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Background: Treatment decisions in colorectal cancer subsequent to surgery are based mainly on the TNM system.
There is a need to establish novel prognostic markers based on the molecular characterization of tumor cells.
Evidence exists that sialyl LeX expression is correlated with an unfavorable outcome in colorectal cancer. The aim of
this study was to establish a simple sialyl LeX staining score and to determine a potential correlation with the
prognosis in a series of advanced colorectal carcinoma patients.
Methods: In order to implement routine use of sialyl LeX immunohistology, we established a new, easily
reproducible score and defined a cutoff which discriminated groups with better or worse outcome, respectively.
We then correlated sialyl LeX expression of 215 UICC stage III and IV patients with disease-free and cancer-related
survival.
Results: A five-stage score could be established based on automated immunohistochemical stainings. Using a
statistical model, we calculated a cutoff to discriminate between weak and strong staining positivity of sialyl LeX.
Patients with strong positive specimens had a worse cancer-related survival (P= 0.004) but no difference was
observed for disease-free survival (P= 0.352).
Conclusions: These results demonstrate a strong correlation between high sialyl LeX-expression in colorectal
carcinomas and cancer-related survival. Our highly standardized and easy-to-use staining score is suitable for
routine use and hence it could be recommended to evaluate sialyl LeX-expression as part of the standard
histopathological analysis of colorectal carcinomas and to validate the score prospectively based on a
larger population.
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Colorectal cancer (CRC) is one of the most important
causes of cancer-related death in the Western world. In
Germany, approximately 71,400 patients develop CRC
per year [1]. Most cancer-related deaths are not caused
by the primary cancer site, but by distant metastasis.
However, patients without distant metastasis at the time
of surgery (International Union Against Cancer (UICC)
stages I to III) still have unsatisfying five-year survival
rates between 41% and 96% [2,3].* Correspondence: leif.schiffmann@med.uni-rostock.de
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distribution, and reproduction in any mediumAdjuvant chemotherapy is generally recommended for
UICC III and IV tumors despite the associated toxicities
[4,5]. Patients’ outcome varies widely between stages
with a worse outcome from stage I to IV, but also within
each stage. This is presumably due to diverse tumor
phenotypes. The challenge lies in the definition of new
prognostic markers for the identification of patients with
a worse outcome. By identifying those patients, it would
be possible to extend the indication for an adjuvant
treatment to UICC stages I and II as well as for a more
aggressive first-line adjuvant therapy in UICC stage III
patients or palliative therapy in UICC stage IV patients.
In recent years, the terminal tetrasaccharide sialyl LeX
has been proposed as a promising prognostic candidate
[6-8]. Its expression is increased with higher tumor stagetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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each stage. However, so far, evaluation of sialyl LeX ex-
pression has not become a standard in the histological
analysis of colorectal carcinoma for diagnostic purposes
or for therapeutic decision making.
Physiologically, sialyl LeX is an E-selectin ligand carbo-
hydrate structure and one of the most important blood
group antigens. It is displayed on the terminus of glyco-
lipids that are present on the cell surface. Sialyl LeX is
constitutively expressed on granulocytes and monocytes
and mediates inflammatory extravasation of these cells
[9,10]. Its capacity to permit cellular motility in conjunc-
tion with mucins explains its contribution to tumor cell
spreading and metastasis [11].
We here report the development of a novel reprodu-
cible sialyl LeX expression score which investigates the
relationship between sialyl LeX expression and prognosis
in a series of patients with colorectal cancer.Methods
Patients
From January 2000 to December 2004, 516 patients
underwent radical surgery for CRC in the department of
General, Thoracic, Vascular und Transplantation Surgery.
All patients were treated according to standard treatment
guidelines [12]. A preoperative anesthesiological evalu-
ation was obtained according to the American Society
of Anesthesiologists (ASA) general classification [13] to
determine state of health and comorbidity. Preoperative
staging involved endoscopy and biopsy, abdomen ultra-
sound or computer tomography and chest radiography. In
case of rectal cancer, an additional endoluminal ultra-
sound for local staging was performed. Furthermore,
patients with a locally advanced rectal cancer (≥ T3 or N+)
received neoadjuvant radiochemotherapy as described pre-
viously [14]. Starting in January 2002, 5-fluoruracil (FU)
treatment was changed to capecitabine.
Patients were staged according to the tumor node
metastasis (TNM) system [15]. Clinical data was retrieved
retrospectively. Data recorded included gender, type of
admission, comorbidities, ASA-score, tumor characteris-
tics, type of resection, morbidity and 30-day mortality.
Follow-up information was recorded regarding recurrence
and distant metastasis, overall survival and cancer-related
survival as well as information about adjuvant therapy
in early 2010. This systematic approach enabled a com-
prehensive data collection. The study was approved
by the ethics committee of the medical faculty of
Rostock University.
In total, 278 stage III and IV patients were identified.
Quality assurance of collected tumor material (H & E
stains) resulted in 215 tumors that were finally analyzed
for sialyl LeX expression.Immunohistochemical staining
From each paraffin-embedded tumor, sections of
4 μm were cut and mounted on polysine-covered
slides. As primary antibody, the monoclonal anti-sialyl LeX
mouse-immunoglobulin M (IgM) (clone KM93, Kamiya
Biomedical Company, Seattle, WA, USA) was used.
Immunohistochemistry including deparaffinization and
antigen retrieval was carried out by the fully automated
Menarini Bond MaxTM autostainer (Menarini Diagnostics,
Florence, Italy). After blocking endogenous peroxid-
ase, the primary antibody (diluted 1:120 in PBS) was
incubated on the sections for thirty minutes at room
temperature. Sections were washed and the secondary
antibody, as well as the polymer from the integrated
BondTM Polymer Refine Kit (item number DS9800,
Leica Microsystems, Wetzlar, Germany), were added
for eight minutes each. Mixed DAB refine (Leica
Microsystems) was applied for twenty minutes fol-
lowed by counterstaining with hematoxylin for add-
itional five minutes. The stainings of the control
sections were constant in all runs.
Evaluation of the sialyl LeX-staining
Initially, 100 stained tumor sections were analyzed to
characterize and categorize typical sialyl LeX staining
patterns independently of the tumor stage. We estab-
lished a five-stage score based on the amount of specific-
ally stained tumor cells and the presence of extracellular
mucus staining (Figure 1). It was not necessary to distin-
guish between weak and strong stained extracellular
mucus in the groups with scattered or almost all stained
cells. On the basis of this score, all 215 sections
were classified independently by two examiners. In case
of differing results, the section was reevaluated in a dia-
logue process.
Statistical analysis
Statistical analysis was performed using Statistical Package
for Social Science (SPSS™) version 15.0. Statistical anal-
ysis was done using Pearson’s chi-square test of Fisher’s
exact test. Survival curves were calculated according to
the Kaplan-Meier method. Survival curves were tested
for significant differences using the log-rank test. A
P value of <0.05 was considered as statistically significant.
The martingale residuals [16] were calculated and
represented by a smoothed residual plot [17] to deter-
mine if and which cutoff value of the sialyl LeX-score
would allow the best separation of the groups of patients
with short- and long-term survival prognosis.
Results
Patients’ characteristics as well as an overview of the
therapeutic regimen of the included 215 cases with stage
III and IV CRC are listed in Table 1. As expected,
Figure 1 Showcase the image sections of the five typical immunohistochemical staining patterns of sialyl LeX (100x magnification).
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sification, as well as the tumor grading, showed a signifi-
cant difference in cancer-related survival (data not shown).
Our sialyl LeX evaluation score is shown in Figure 1.
Basically, we distinguished between the proportion of
stained cells with an extra category for extracellular
stained mucus. The smoothed residual plot in Figure 2
indicates an increase in the risk of cancer-related death
from score two to three. So we separated our patientsTable 1 Patients’ characteristics
Patients n (%)
Patients 215 (100)
Mean age (years) 67.4
Gender ratio (f/m) 1:1.26 (95:120)
Rectal cancer patients 73 (34.0)
Neoadjuvant radiochemotherapy 7 (9.6)
Colon and rectal cancer patients UICC stage III 113 (52.6)
Adjuvant (radio-) chemotherapy 89 (78.8)
Colon and rectal cancer patients UICC stage IV 102 (47.4)
Palliative (radio-) chemotherapy 62 (60.8)
Tumor location
Right hemicolon 62 (43.7)
Transverse colon 18 (12.7)
Left hemicolon 6 (4.2)
Sigmoid colon 56 (39.4)
Rectum 73 (34.0)into two risk groups with a staining score from zero to
two (the low-risk group with weak sialyl LeX expression)
and three to four (the high-risk group with strong sialyl
LeX expression). One hundred and thirteen colorectal
tumors (52.6%) were found to express sialyl LeX weakly
whereas 102 tumors (47.4%) showed a stronger expres-
sion. The survival curves for these two groups differ
significantly and thus prove a difference in cancer-related
survival (P= 0.004, Figure 3A). This difference persistsFigure 2 Martingale residuals as a function of the sialyl LeX
staining score. Each dot represents the difference between the
observed individual status and the calculated cumulative risk at the
end of the observation period.
Figure 3 Cancer-related survival after resection of colorectal cancer depending on sialyl LeX expression stages III and IV (A), stage III
alone (B) and stage IV alone (C).
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IV patients separately (P= 0.044, Figure 3C). However,
there was no difference in disease-free survival between
the two patient groups with weak and strong sialyl LeX
expression (P= 0.352). Likewise, the increase of sialyl LeX
expression in carcinomas with UICC stage III (43.4%) and
IV (52.0%) was not statistically significant in our patient
population (P=0.131). Distribution of age, gender, com-
mon histopathological features and tumor localization
were comparable between weak and strong sialyl LeX-
expressing carcinomas (Table 2).
Discussion
Long-term survival of CRC patients is limited by metas-
tasis rather than by the primary tumor itself. So far,
an adjuvant treatment is administrated based on prog-
nosis determined by the UICC stage. However, the
TNM system does not allow stratification of certain sub-
groups of patients in whom the outcome is predominantly
determined by tumor cell-specific molecular characteris-
tics. This underlines the need for additional prognostic
markers.
The tetrasaccharide carbohydrate sialyl LeX appears
to be a promising candidate marker to reflect tumoraggressiveness. Several groups proposed that immuno-
histochemical assessment of sialyl LeX expression is of
prognostic relevance [6-8].
In the present work, we analyzed tumor sections of 215
colorectal carcinoma patients with a documented follow-
up. Because the correlation of stronger sialyl LeX expres-
sion with higher UICC stages has been shown previously
[8] and shorter survival times make statistical evaluation
more feasible, we analyzed only stage III and IV patients.
Our patient cohort is representative since there was a
correlation with survival and the well-established prog-
nostic markers T, N and G as well as the UICC stages.
Immunohistochemistry is ideal to depict sialyl LeX ex-
pression since PCR is not the method of choice to
analyze carbohydrates and in Western blot the sialyl LeX
signals may be distributed from different cellular com-
partments. The differentiation between staining signals
generated by the extracellular mucus and the cell mem-
brane is a main challenge in evaluating sialyl Lex expres-
sion. Only the latter is thought to be basically linked
with the extravasation of tumor cells [18]. So far, this
discrimination has not been achieved [6-8,19]. To limit
variance in staining, we chose a fully automated proces-
sing of the slides.
Table 2 Clinical and histopathological criteria stratified





Patients 113 (52.6) 102 (47.4)
Mean age (years) 67.2 67.6
Gender ratio (f/m) 1:1.57 (44:69) 1:1 (51:51)
Infiltration (pT)
T1 2 (1.8) 0 (0.0)
T2 13 (11.5) 6 (5.9)
T3 54 (47.8) 42 (41.2)
T4 44 (38.9) 54 (52.9)
Lymph node metastasis (pN)
N0 10 (8.8) 9 (8.8)
N1 61 (54.0) 39 (38.2)
N2 42 (37.2) 54 (52.9)
Metastasis
M0 64 (56.6) 49 (48.0)
M1 49 (43.4) 53 (52.0)
Grading
G1 18 (15.9) 26 (25.5)
G2 79 (69.9) 70 (68.6)
G3 16 (14.2) 6 (5.9)
Localization
Colon 70 (61.9) 72 (70.6)
Rectum 43 (38.1) 30 (29.4)
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score based on staining intensity as well as the percent-
age of stained cells, as suggested by Grabowski et al. [8],
might not be reproducible even when using automated
staining systems. Staining intensity especially could vary
by minor changes in concentrations, staining time or the
age of the staining components. The group of Nakamori
[6] distinguished between negative- and positive-stained
cells with a cutoff at 5%. Nakagoe et al. [7] categorized
four groups with cutoffs at 5%, 40% and 80%. These
approaches were not widely accepted, possibly due to
the fact that natural staining patterns were not consid-
ered sufficient. Variations as well as difficulties in inter-
pretation of staining might have limited the acceptance
of the previous techniques. Therefore, we defined a
score that allows an easy categorization independent
from staining intensities. It takes into account the pro-
portion of positive tumor cells and the staining of the
extracellular mucus. Principally, it appears possible to
merge the categories of sporadic positively stained cells
with and without extracellular mucus (score 1 and 2) to
one category.
As a statistical model to distinguish between groups
with higher and lower risk of tumor-related death, we
used the martingale residuals [16,17,20]. The best cutoffwas detected between a score of two and three, by which
we could confirm the correlation between sialyl LeX
expression and tumor-related survival found by others
[6-8]. However, our findings differ in some points. First,
unlike Grabowski and coworkers [8], we observed a sig-
nificant difference in survival in UICC stage III as well
as IV. This finding raises some skepticism to their
hypothesis that there is no influence of sialyl LeX expres-
sion in UICC stage IV patients due to pre-existing
metastases. The difference in survival observed by us
may partly be explained by the fact that, unlike multiple
metastases, a single metastasis or limited metastatic dis-
ease do not necessarily limit patients’ long-term survival
[21,22]. Surgical approaches have become much more
aggressive with a survival benefit for the patients. Sec-
ond, we observed no significant difference in disease-free
survival in stage III patients between the two groups
with low and high sialyl LeX expression. Previous studies
did not focus on this question [6,8]. Thus, future studies
with prolonged follow-up time and increased patient
numbers might identify significant differences.
Comparable to literature data, we found no correlation
between sialyl LeX expression and other histopatho-
logical markers like TNM or grading [6-8]. The increase
of sialyl LeX expression from carcinomas of UICC stage
III (43.4%) to stage IV (52.0%) was not significant in the
presented study. This fact might be a problem with the
size of the study population and might become signifi-
cant in a larger study cohort.
Conclusions
In conclusion, our data strongly support previous find-
ings that increased sialyl LeX expression is predictive for
a worse outcome. We developed an easy scoring system
feasible to distinguish between weak and strong sialyl
LeX expression. A significant difference was observed for
cancer-related survival but not for disease-free survival.
In consequence, we recommend sialyl LeX immunohis-
tochemistry to be further evaluated on a routine basis.
When taking into account previous studies on sialyl LeX
expression, it seems promising to use it as an independ-
ent prognostic marker to identify subgroups of patients
with a worse prognosis.
Competing interests
The authors declare that they have no competing interests.
Acknowledgement
This work was financially supported by Schaustellerverein Rostock. Special
acknowledgement is given to Mr. T. Brüning for establishing the
immunohistochemistry on the fully automated Merarini BondMaxTM
autostainer and Mrs. D. Frenz for helping prepare the paraffin slides.
Author details
1Department of General, Thoracic, Vascular and Transplantation Surgery,
University of Rostock, Schillingallee 35, 18057 Rostock, Germany. 2Institute of
Pathology, University of Rostock, Strempelstrasse 14, 18055 Rostock, Germany.
Schiffmann et al. World Journal of Surgical Oncology 2012, 10:95 Page 6 of 6
http://www.wjso.com/content/10/1/953Department of Neurology, Neurodegeneration Research Laboratory (NRL) and
German National Dementia Center (DZNE), University of Rostock, Gehlsheimer
Strasse 20, 18147 Rostock, Germany. 4Institute for Biostatistics and Informatics in
Medicine and Ageing Research, University of Rostock, Ernst-Heydemann-Strasse
8, 18057 Rostock, Germany. 5Institute for Experimental Surgery, University of
Rostock, Schillingallee 57, 18057 Rostock, Germany.Authors’ contributions
LS and FS conceived and coordinated the study, collected patients’ data,
participated in the analysis of the specimens and statistical analysis. LS
drafted the manuscript. FP identified the paraffin blocks and participated in
preparing the manuscript. JP established the automated staining and
participated in developing the new score. HK participated in the statistical
analysis. BV participated in conceiving and coordinating the study and
preparing the manuscript. ML and EK participated in preparing and drafting
the manuscript. All authors read and approved the final manuscript.
Received: 20 February 2012 Accepted: 23 May 2012
Published: 23 May 2012References
1. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. and Robert
Koch-Institut, Krebs in Deutschland - Häufigkeiten und Trends. 5th edition.
Saarbrücken: Gesellschaft der epidemiologischen Krebsregister in
Deutschland e.V; 2006:p108.
2. Staib L, Link KH, Blatz A, Beger HG: Surgery of colorectal cancer: surgical
morbidity and five- and ten-year results in 2400 patients – a
monoinstitutional experience. World J Surg 2002, 26:59–66.
3. Davis NC, Evans EB, Cohen JR, Theile DE, Job DM: Colorectal cancer: a
large unselected Australian series. Aust N Z J Surg 1987, 57:153–159.
4. Chau I, Cunningham D: Treatment in advanced colorectal cancer: what,
when and how? Br J Cancer 2009, 100:1704–1719.
5. Meyerhardt JA, Mayer RJ: Systemic therapy for colorectal cancer. NEJM
2005, 352:476–487.
6. Nakamori S, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, Sasaki Y,
Kabuto T, Iwanaga T, Matsushita Y, Irimura T: Increased expression of sialyl
Lewis x antigen correlates with poor survival in patients with colorectal
carcinoma: clinicopathological and immunohistochemical study.
Cancer Res 1993, 53:3632–3637.
7. Nakagoe T, Fukushima K, Hirota M, Kusano H, Ayabe H, Tomita M, Kamihira
S: Immunohistochemical expression of sialyl Lex antigen in relation to
survival of patients with colorectal carcinoma. Cancer 1993, 72:2323–2330.
8. Grabowski P, Mann B, Mansmann U, Lövin N, Foss HD, Berger G, Scherübl H,
Riecken EO, Buhr HJ, Hanski C: Expression of sialyl-Le(x) antigen defined
by MAb AM-3 is an independent prognostic marker in colorectal
carcinoma patients. Int J Cancer 2000, 88:281–286.
9. Sperandio M: Selectins and glycosyltransferases in leukocyte rolling
in vivo. FEBS J 2006, 273:4377–4389.
10. Zimmerman BJ, Paulson JC, Arrhenius TS, Gaeta FCA, Granger DN:
Thrombin receptor peptide-mediated leukocyte rolling in rat mesenteric
venules: roles of P-selectin and sialyl Lewis X. Am J Physiol 1994,
267:H1049–H1053.
11. Byrd JC, Bresalier RS: Mucins and mucin-binding proteins in colorectal
cancer. Cancer Metastasis Rev 2004, 23:77–99.
12. AWMF. Accessed 25 March 2009. http://www.awmf-online.de.
13. Dripps AD, Lamont A, Eckenhoff JE: The role of anesthesia in surgical
mortality. JAMA. 1961, 178:261–266.
14. Klautke G, Feyerherd F, Ludwig K, Prall F, Foitzik T, Fietkau R: Intensified
concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as
neoadjuvant treatment in patients with locally advanced rectal cancer.
Br J Cancer 2005, 92:1215–1220.
15. TNM Classification of Malignant Tumors. 5th edition. New York: J. Wiley &
Sons; 1997.
16. Klein JP, Moeschberger ML: Survival analysis: techniques for censored and
truncated data. New York: Springer; 1997.
17. Therneau TM, Grambsch PM, Flemenig TR: Martingale-based residuals for
survival models. Biometrika 1990, 77:147–160.
18. St Hill CA, Baharo-Hassan D, Farooqui M: C2-O-sLeX glycoproteins are
E-selectin ligands that regulate invasion of human colon and hepatic
carcinoma cells. PLoS One 2011, 6:e16281.19. Matsushita Y, Yamamoto N, Shirahama H, Tanaka S, Yonezawa S, Yamori T,
Irimura T, Sato E: Expression of sulfomucins in normal mucosae,
colorectal adenocarcinomas, and metastases. Jpn J Cancer Res 1995,
86:1060–1067.
20. Fleming TR, Harrington DP: Counting Processes and Survival Analysis.
Indianapolis: Wiley-Interscience; 2005:448.
21. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH: Clinical score for
predicting recurrence after hepatic resection for metastatic colorectal
cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230:309–318.
22. Lee WS, Kim MJ, Yun SH, Chun HK, Lee WY, Kim SJ, Choi SH, Heo JS, Joh
JW, Kim YI: Risk factor stratification after simultaneous liver and
colorectal resection for synchronous colorectal metastasis. Langenbecks
Arch Sur 2008, 393:13–19.
doi:10.1186/1477-7819-10-95
Cite this article as: Schiffmann et al.: A novel sialyl LeX expression score
as a potential prognostic tool in colorectal cancer. World Journal of
Surgical Oncology 2012 10:95.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
